Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.
NEW YORK Pfizer Inc on Tuesday reported lower-than-expected first-quarter revenue as demand for some key drugs and international sales fell short of estimates, sparking a 5.1 percent drop in shares of the largest U.S. drugmaker. | Video
Laboratory Corp of America Holdings posted a quarterly profit on Wednesday that beat analysts' estimates, helped by higher demand at the unit performing clinical trials for drugmakers, and prompting the company to raise its full-year revenue target.
Alexion Pharmaceuticals Inc said its experimental drug to treat a rare blood disorder showed in an eagerly awaited study that it was not inferior to its flagship drug, Soliris, paving the way for the company to establish a dominant position in the market as competition looms.
Dermira Inc will discontinue development of its acne drug after the treatment failed to meet the main goals of two late-stage studies, the company said on Monday.
Biogen Inc and AbbVie Inc have withdrawn their multiple sclerosis drug, the companies said on Friday, following reports of eight cases of inflammation of the brain, prompting the European Medicines Agency (EMA) to start an urgent review.
Endo International Plc's full-year revenue and profit forecasts fell short of Street estimates, due to continued pressure on its generics business and increased competition, sending its shares down nearly 5 percent in on Tuesday.
Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio .
Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million (£628.8 million) to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.
Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.